Advertisement
Screener

NATURE’S SUNSHINE PRODUCTS, INC. (NATR) Net Income (Loss) Available to Common Stockholders, Basic

1.8 / 5 stars · 41/112 Roast Me

NATURE’S SUNSHINE PRODUCTS, INC. Net Income (Loss) Available to Common Stockholders, Basic

NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Net Income (Loss) Available to Common Stockholders, Basic of $3.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Net Income

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06

  • NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $3.54M, a 33.66% decline year-over-year.
  • NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $5.12M, a 7.82% increase year-over-year.
  • NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $4.11M.
  • NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $5.33M, a 22.71% increase year-over-year.
  • NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was $19.52M, a 153.65% increase from fiscal 2024.
  • NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was $7.70M, a 48.95% decline from fiscal 2023.
  • NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was $15.08M.
  • NATURE’S SUNSHINE PRODUCTS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$390.00K, a 101.35% decline from fiscal 2021.
Period endNet Income (Loss) Available to Common Stockholders, Basic 3 monthNet Income (Loss) Available to Common Stockholders, Basic 6 monthNet Income (Loss) Available to Common Stockholders, Basic 9 monthNet Income (Loss) Available to Common Stockholders, Basic 12 month
2026-06-30$3.54M
10-Q · filed 2026-08-06
$8.66M
10-Q · filed 2026-08-06
$12.76M
derived: sum of 3 quarters · filed 2026-08-06
$18.10M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$5.12M
10-Q · filed 2026-05-07
$9.22M
derived: sum of 2 quarters · filed 2026-05-07
$14.56M
derived: sum of 3 quarters · filed 2026-05-07
$19.89M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$4.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10
$9.44M
derived: sum of 2 quarters · filed 2026-03-10
$14.77M
derived: sum of 3 quarters · filed 2026-08-06
$19.52M
10-K · filed 2026-03-10
2025-09-30$5.33M
10-Q · filed 2025-11-06
$10.67M
derived: sum of 2 quarters · filed 2026-08-06
$15.41M
10-Q · filed 2025-11-06
$15.09M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$5.33M
10-Q · filed 2026-08-06
$10.08M
10-Q · filed 2026-08-06
$9.76M
derived: sum of 3 quarters · filed 2026-08-06
$14.11M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$4.75M
10-Q · filed 2026-05-07
$4.43M
derived: sum of 2 quarters · filed 2026-05-07
$8.77M
derived: sum of 3 quarters · filed 2026-05-07
$10.12M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$321.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10
$4.03M
derived: sum of 2 quarters · filed 2026-03-10
$5.38M
derived: sum of 3 quarters · filed 2026-03-10
$7.70M
10-K · filed 2026-03-10
2024-09-30$4.35M
10-Q · filed 2025-11-06
$5.70M
derived: sum of 2 quarters · filed 2025-11-06
$8.02M
10-Q · filed 2025-11-06
$16.98M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30$1.35M
10-Q · filed 2025-07-31
$3.67M
10-Q · filed 2025-07-31
$12.63M
derived: sum of 3 quarters · filed 2025-07-31
$15.46M
derived: sum of 4 quarters · filed 2025-07-31
2024-03-31$2.32M
10-Q · filed 2025-05-06
$11.28M
derived: sum of 2 quarters · filed 2025-05-06
$14.12M
derived: sum of 3 quarters · filed 2025-05-06
$16.54M
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31$8.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$11.79M
derived: sum of 2 quarters · filed 2025-03-11
$14.22M
derived: sum of 3 quarters · filed 2025-03-11
$15.08M
10-K · filed 2025-03-11
2023-09-30$2.83M
10-Q · filed 2024-11-07
$5.25M
derived: sum of 2 quarters · filed 2024-11-07
$6.11M
10-Q · filed 2024-11-07
$8.07M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30$2.42M
10-Q · filed 2024-08-08
$3.28M
10-Q · filed 2024-08-08
$5.24M
derived: sum of 3 quarters · filed 2024-08-08
$5.33M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$860.00K
10-Q · filed 2024-05-07
$2.81M
derived: sum of 2 quarters · filed 2024-05-07
$2.90M
derived: sum of 3 quarters · filed 2024-05-07
$3.42M
derived: sum of 4 quarters · filed 2024-05-07
2022-12-31$1.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
$2.04M
derived: sum of 2 quarters · filed 2024-03-12
$2.56M
derived: sum of 3 quarters · filed 2024-03-12
-$390.00K
10-K · filed 2024-03-12
2022-09-30$90.00K
10-Q · filed 2023-11-07
$606.00K
derived: sum of 2 quarters · filed 2023-11-07
-$2.34M
10-Q · filed 2023-11-07
$11.10M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$516.00K
10-Q · filed 2023-08-09
-$2.43M
10-Q · filed 2023-08-09
$11.01M
derived: sum of 3 quarters · filed 2023-08-09
$15.86M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$2.95M
10-Q · filed 2023-05-09
$10.49M
derived: sum of 2 quarters · filed 2023-05-09
$15.35M
derived: sum of 3 quarters · filed 2023-05-09
$21.89M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$13.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
$18.30M
derived: sum of 2 quarters · filed 2023-03-16
$24.84M
derived: sum of 3 quarters · filed 2023-03-16
$28.85M
10-K · filed 2023-03-16
2021-09-30$4.86M
10-Q · filed 2022-11-03
$11.40M
derived: sum of 2 quarters · filed 2022-11-03
$15.41M
10-Q · filed 2022-11-03
$21.28M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30$6.54M
10-Q · filed 2022-08-09
$10.56M
10-Q · filed 2022-08-09
$16.42M
derived: sum of 3 quarters · filed 2022-08-09
$23.18M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$4.02M
10-Q · filed 2022-05-05
$9.88M
derived: sum of 2 quarters · filed 2022-05-05
$16.64M
derived: sum of 3 quarters · filed 2022-05-05
$22.39M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31$5.87M
10-K · filed 2021-03-10
$12.62M
derived: sum of 2 quarters · filed 2021-11-04
$18.38M
derived: sum of 3 quarters · filed 2021-11-04
$21.34M
10-K · filed 2022-03-08
2020-09-30$6.75M
10-Q · filed 2021-11-04
$12.51M
derived: sum of 2 quarters · filed 2021-11-04
$15.47M
10-Q · filed 2021-11-04
$16.47M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30$5.75M
10-Q · filed 2021-08-05
$8.72M
10-Q · filed 2021-08-05
$9.72M
derived: sum of 3 quarters · filed 2021-08-05
$11.04M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$2.96M
10-Q · filed 2021-05-06
$3.96M
derived: sum of 2 quarters · filed 2021-05-06
$5.28M
derived: sum of 3 quarters · filed 2021-05-06
$7.97M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31$1.00M
10-K · filed 2021-03-10
$2.32M
derived: sum of 2 quarters · filed 2021-03-10
$5.01M
derived: sum of 3 quarters · filed 2021-03-10
$6.76M
10-K · filed 2021-03-10
2019-09-30$1.32M
10-K · filed 2021-03-10
$4.01M
derived: sum of 2 quarters · filed 2021-03-10
$5.76M
10-Q · filed 2020-11-09
$2.85M
derived: sum of 4 quarters · filed 2021-03-10
2019-06-30$2.69M
10-K · filed 2021-03-10
$4.45M
10-Q · filed 2020-08-06
$1.53M
derived: sum of 3 quarters · filed 2021-03-10
$3.03M
derived: sum of 4 quarters · filed 2021-03-10
2019-03-31$1.76M
10-K · filed 2021-03-10
-$1.16M
derived: sum of 2 quarters · filed 2021-03-10
$338.00K
derived: sum of 3 quarters · filed 2021-03-10
$405.00K
derived: sum of 4 quarters · filed 2021-03-10
2018-12-31-$2.92M
10-K · filed 2020-03-11
-$1.42M
derived: sum of 2 quarters · filed 2020-03-11
-$1.35M
derived: sum of 3 quarters · filed 2020-03-11
-$854.00K
10-K · filed 2020-03-11
2018-09-30$1.50M
10-K · filed 2020-03-11
$1.56M
derived: sum of 2 quarters · filed 2020-03-11
$2.06M
10-Q · filed 2019-11-07
-$15.30M
derived: sum of 4 quarters · filed 2020-03-11
2018-06-30$67.00K
10-K · filed 2020-03-11
$565.00K
10-Q · filed 2019-08-09
-$16.79M
derived: sum of 3 quarters · filed 2020-03-11
-$14.35M
derived: sum of 4 quarters · filed 2020-03-11
2018-03-31$498.00K
10-K · filed 2020-03-11
-$16.86M
derived: sum of 2 quarters · filed 2020-03-11
-$14.42M
derived: sum of 3 quarters · filed 2020-03-11
-$14.60M
derived: sum of 4 quarters · filed 2020-03-11
2017-12-31-$17.36M
10-K · filed 2019-03-08
-$14.91M
derived: sum of 2 quarters · filed 2019-03-08
-$15.10M
derived: sum of 3 quarters · filed 2019-03-08
-$12.94M
10-K · filed 2019-03-08
2017-09-30$2.44M
10-K · filed 2019-03-08
$2.26M
derived: sum of 2 quarters · filed 2019-03-08
$4.42M
10-Q · filed 2018-11-08
-$2.24M
derived: sum of 4 quarters · filed 2019-03-08
2017-06-30-$187.00K
10-K · filed 2019-03-08
$1.97M
10-Q · filed 2018-08-08
-$4.68M
derived: sum of 3 quarters · filed 2019-03-08
-$525.00K
derived: sum of 4 quarters · filed 2019-03-08
2017-03-31$2.16M
10-K · filed 2019-03-08
-$4.49M
derived: sum of 2 quarters · filed 2019-03-08
-$338.00K
derived: sum of 3 quarters · filed 2019-03-08
$2.23M
derived: sum of 4 quarters · filed 2019-03-08
2016-12-31-$6.65M
10-K · filed 2018-03-16
-$2.50M
derived: sum of 2 quarters · filed 2018-03-16
$70.00K
derived: sum of 3 quarters · filed 2018-03-16
$2.14M
10-K · filed 2019-03-08
2016-09-30$4.16M
10-K · filed 2018-03-16
$6.72M
derived: sum of 2 quarters · filed 2018-03-16
$8.79M
10-Q · filed 2017-11-09
$12.48M
derived: sum of 4 quarters · filed 2018-03-16
2016-06-30$2.57M
10-K · filed 2018-03-16
$4.64M
10-Q · filed 2017-08-09
$8.33M
derived: sum of 3 quarters · filed 2018-03-16
$11.10M
derived: sum of 4 quarters · filed 2018-03-16
2016-03-31$2.07M
10-K · filed 2018-03-16
$5.76M
derived: sum of 2 quarters · filed 2018-03-16
$8.53M
derived: sum of 3 quarters · filed 2018-03-16
$11.09M
derived: sum of 4 quarters · filed 2018-03-16
2015-12-31$3.69M
10-K · filed 2017-03-14
$6.46M
derived: sum of 2 quarters · filed 2017-03-14
$9.02M
derived: sum of 3 quarters · filed 2017-03-14
$14.69M
10-K · filed 2018-03-16
2015-09-30$2.77M
10-K · filed 2017-03-14
$5.33M
derived: sum of 2 quarters · filed 2017-03-14
$10.99M
10-Q · filed 2016-11-09
$7.10M
derived: sum of 4 quarters · filed 2017-03-14
2015-06-30$2.56M
10-K · filed 2017-03-14
$8.23M
10-Q · filed 2016-08-09
$4.33M
derived: sum of 3 quarters · filed 2017-03-14
$5.35M
derived: sum of 4 quarters · filed 2017-03-14
2015-03-31$5.67M
10-K · filed 2017-03-14
$1.77M
derived: sum of 2 quarters · filed 2017-03-14
$2.79M
derived: sum of 3 quarters · filed 2017-03-14
$6.02M
derived: sum of 4 quarters · filed 2017-03-14
2014-12-31-$3.90M
10-K · filed 2016-03-14
-$2.88M
derived: sum of 2 quarters · filed 2016-03-14
$354.00K
derived: sum of 3 quarters · filed 2016-03-14
$10.02M
10-K · filed 2017-03-14
2014-09-30$1.02M
10-K · filed 2016-03-14
$4.25M
derived: sum of 2 quarters · filed 2016-03-14
$13.92M
10-Q · filed 2015-11-06
$15.76M
derived: sum of 4 quarters · filed 2016-03-14
2014-06-30$3.23M
10-K · filed 2016-03-14
$12.90M
10-Q · filed 2015-08-10
$14.74M
derived: sum of 3 quarters · filed 2016-03-14
$19.59M
derived: sum of 4 quarters · filed 2016-03-14
2014-03-31$9.66M
10-K · filed 2016-03-14
$11.51M
derived: sum of 2 quarters · filed 2016-03-14
$16.36M
derived: sum of 3 quarters · filed 2016-03-14
$22.41M
derived: sum of 4 quarters · filed 2016-03-14
2013-12-31$1.84M
10-K · filed 2015-03-13
$6.69M
derived: sum of 2 quarters · filed 2015-03-13
$12.74M
derived: sum of 3 quarters · filed 2015-03-13
$17.61M
10-K · filed 2016-03-14
2013-09-30$4.85M
10-K · filed 2015-03-13
$10.90M
derived: sum of 2 quarters · filed 2015-03-13
$15.77M
10-Q · filed 2014-11-06
$20.26M
derived: sum of 4 quarters · filed 2015-03-13
2013-06-30$6.05M
10-K · filed 2015-03-13
$10.92M
10-Q · filed 2014-08-07
$15.41M
derived: sum of 3 quarters · filed 2015-03-13
$21.78M
derived: sum of 4 quarters · filed 2015-03-13
2013-03-31$4.86M
10-K · filed 2015-03-13
$9.36M
derived: sum of 2 quarters · filed 2015-03-13
$15.73M
derived: sum of 3 quarters · filed 2015-03-13
$23.02M
derived: sum of 4 quarters · filed 2015-03-13
2012-12-31$4.50M
10-K · filed 2014-03-17
$10.87M
derived: sum of 2 quarters · filed 2014-03-17
$18.15M
derived: sum of 3 quarters · filed 2014-03-17
$25.38M
10-K · filed 2015-03-13
2012-09-30$6.37M
10-K · filed 2014-03-17
$13.66M
derived: sum of 2 quarters · filed 2014-03-17
$20.88M
10-Q · filed 2013-11-08
$28.50M
derived: sum of 4 quarters · filed 2014-03-17
2012-06-30$7.29M
10-K · filed 2014-03-17
$14.51M
10-Q · filed 2013-08-09
$22.14M
derived: sum of 3 quarters · filed 2014-03-17
$19.88M
derived: sum of 4 quarters · filed 2014-03-17
2012-03-31$7.23M
10-K · filed 2014-03-17
$14.85M
derived: sum of 2 quarters · filed 2014-03-17
$12.59M
derived: sum of 3 quarters · filed 2014-03-17
$18.21M
derived: sum of 4 quarters · filed 2014-03-17
2011-12-31$7.62M
10-K · filed 2013-03-07
$5.37M
derived: sum of 2 quarters · filed 2013-03-07
$10.98M
derived: sum of 3 quarters · filed 2013-03-07
$17.60M
10-K · filed 2014-03-17
2011-09-30-$2.26M
10-K · filed 2013-03-07
$3.36M
derived: sum of 2 quarters · filed 2013-03-07
$9.98M
10-Q · filed 2012-11-06
$9.28M
derived: sum of 4 quarters · filed 2013-03-07
2011-06-30$5.61M
10-K · filed 2013-03-07
$12.24M
10-Q · filed 2012-08-03
$11.54M
derived: sum of 3 quarters · filed 2013-03-07
$5.80M
derived: sum of 4 quarters · filed 2013-03-07
2011-03-31$6.62M
10-K · filed 2013-03-07
$5.92M
derived: sum of 2 quarters · filed 2013-03-07
$182.00K
derived: sum of 3 quarters · filed 2013-03-07
2010-12-31-$700.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-07
-$6.44M
derived: sum of 2 quarters · filed 2013-03-07
-$1.23M
10-K · filed 2013-03-07
2010-09-30-$5.74M
10-Q · filed 2011-11-08
-$533.00K
10-Q · filed 2011-11-08
2009-12-31$6.12M
10-K · filed 2012-03-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Foghorn Therapeutics Inc. (FHTX)United States$0.213B-4.43
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01